A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes in Chinese Population

Exclusion Criteria

• -history of alcohol or drug abuse within the past year
• -pregnant at time of an assessment
• -has an altered mental status at the time of informed consent
• -receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
• -history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
• -terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
• -Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.